Abstract
Springer-Verlag 2007 With the new legislation in Germany, cost-benefit assessment can be used to stipulate maximum reimbursement amounts for pharmaceuticals. According to the law, the Institute for Quality and Efficiency in the Health Care Sector (IQWiG) can be commissioned by the Federal Joint Committee (G-BA) and the Ministry of Health with the assessment of benefits or the cost-benefit ratio of pharmaceuticals. The results of the commissioned economic evaluation studies, or those conducted by the initiative of the Institute itself, will serve as a decision-making basis for the institutions in charge of making reimbursement decisions, the Federal Joint Committee (G-BA) or the Head
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
